Protagonist returns to profit in Q2 FY26 with net income of $162.85 million
Reuters2026/08/05 20:23- Protagonist Therapeutics swung to GAAP net income of USD 162.85 million in Q2 2026 from a loss a year earlier; diluted EPS was USD 2.29.
- GAAP revenue climbed to USD 213.48 million from USD 5.55 million, driven mainly by Takeda opt-out payment recognition and development services.
- GAAP RD expense rose to USD 42.06 million from USD 37.04 million; GAAP GA increased to USD 12.65 million from USD 10.55 million.
- Cash, cash equivalents and marketable securities rose to USD 849.45 million at June 30 from USD 646 million at Dec. 31.
- Rusfertide NDA remained under FDA priority review with an August 2026 PDUFA date; ICOTYDE posted its first full quarter of commercial sales.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The first major "exam" after the Cook era! Morgan Stanley: Apple's (AAPL.US) autumn launch event is the most important in ten years; the first foldable iPhone may spark a new wave of growth
Morgan Stanley analysts stated that Apple's upcoming "Surprise and Shine" autumn product launch event on September 9 may become the company's most important product release in nearly a decade.
10-Yr Benchmark Govt Yields - Germany vs Other Nations
2-Yr Benchmark Govt Yields - Germany vs Other Nations
10-Yr Benchmark Govt Yields - U.S. vs Other Nations
Crypto prices
More
